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Introduction
Erectile dysfunction (ED) is defined as the inability to 
achieve and maintain a penile erection adequate for satis-
factory sexual intercourse.1 Up to 150 million men world-
wide suffer from ED and this figure is likely to double by 
the year 2025.2
A number of studies have attempted to characterise the 
true prevalence of ED. In a Danish study, Ventegodt 
reported that 5.4% of all patients had a decreased ability to 
achieve an erection.3 The prevalence was reported to be 
highest (18%) in those aged over 58 years. The 
Massachusetts Male Aging Study (MMAS)4 reported the 
results of a regional survey of 1709 men aged 40–69 years. 
In this study 52% reported some degree of ED, with 10% 
having complete ED. Moreover, the results suggest that the 
probability of complete ED at age 70 was threefold com-
pared to that at age 40; the probability of moderate ED was 
two-fold.
Physiology of penile erection
Penile erection is a complex neurovascular event. The 
degree of contraction or relaxation of the cavernosal smooth 
muscle determines the degree of tumescence or detumes-
cence.5 The balance between the contractile and relaxant 
factors is known to be controlled by both central and 
peripheral mechanisms and involves the interaction of three 
different systems:6 (a) the central nervous system (CNS); 
(b) the peripheral nervous system; and (c) the vascular and 
cavernosal smooth muscle in the penis.
The CNS
The CNS coordinates incoming sensory information from a 
variety of sources which may be visual, auditory, cognitive/
imaginative, tactile or olfactory. The central pathways   
integrating these inputs and controlling erectile function are 
complex and only partially understood. However, there is 
strong evidence to support the involvement of the paraven-
tricular nucleus (PVN) and the medial pre-optic area (MPOA) 
within the hypothalamus in the control of erectile function. 
The MPOA has been postulated to be an integrative centre 
that collects the input and redistributes to other structures 
within the CNS such as the PVN. The PVN in turn has been 
suggested to activate selective autonomic pathways resulting 
in an erection.7 The neurons from the PVN have been 
reported to project onto the spinal cord either directly or via 
the median forebrain bundle, pons and medulla. The descend-
ing pathways from the PVN to the spinal cord have been 
reported to contain a variety of neurotransmitters such as 
oxytocin, vasopressin, encephalin and dopamine.7
The peripheral nervous system
Within the spinal cord, there are various specific areas 
which contain integral components of the erectile sys-
tem. These are known as the “erection centres” (Figure 
1). The thoraco-lumbar erection centre is located 
between T1 and L2 and gives rise to the sympathetic out-
flow pathway. This connects to the urogenital tract via 
the pelvic, cavernosal and pudendal nerves. The sacral 
erection centre is located between the S2 and S4 seg-
ments of the spinal cord and gives rise to the parasympa-
thetic outflow pathway. These fibres reach the penis via 
the pelvic, cavernosal and pudendal nerves. Further-
more, the penis receives dense somatic input from   
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sensory branches of the dorsal nerve, a branch of the 
pudendal nerve.5
The individual nerves innervating the penis may con-
tain a number of different neurotransmitters and as a 
result the nerves are categorised as either being adrener-
gic or cholinergic according to the predominant trans-
mitter present. However, non-adrenergic non-cholinergic 
(NANC) neurotransmitters may be found and indeed be 
co-localised with either adrenergic or cholinergic 
nerves. Nitric oxide (NO) is one of the NANC neuro-
transmitters which has now been widely accepted to be 
the major mediator eliciting relaxation of the penile 
smooth muscle.9
During sexual arousal, NO has been reported to be 
released from parasympathetic nerve terminals,10 and 
these nerves are therefore called nitrergic nerves.11 NO 
release results in relaxation of the cavernosal smooth 
muscle and vasodilation. Simultaneous compression of 
the subtunical venules results in an erection. Noradrenaline 
released from sympathetic nerves causes contraction of 
the blood vessels and smooth muscle of the corpus caver-
nosum, thus leading to detumescence of the penis. 
Erection of the penis is therefore regulated by a balance 
between pro- and anti-erectile mediators (Figure 2). 
Studies with human corpus cavernosum suggest that when 
the two systems are simultaneously active, the nitrergic 
system is dominant over the sympathetic system.12
Vascular and cavernosal smooth muscle in 
the penis
The human penis is composed of paired corpora cavernosa 
and the single corpus spongiosum (Figure 3). The corpus 
cavernosum consists of a meshwork of sinusoidal spaces 
lined by endothelial cells.5 In order for an erection to occur, 
relaxation of penile smooth muscle is required to allow 
blood to flow into the penile structures. The resulting 
increase in intracavernosal pressure (ICP) leads to com-
pression of the subtunical venules against the tunica albug-
inea.5 This process reduces venous drainage from the 
corpora cavernosa and increases pressure within the cor-
pora, resulting in an erection. In full rigidity the ICP reaches 
values considerably higher than systemic (systolic) blood 
pressure with the contribution of the skeletal muscles of the 
pelvic floor.
Relaxant factors: the NO-soluble 
guanylate cyclase (sGC)-cyclic guanosine 
monophosphate (cGMP) pathway
In 1990 Ignarro et al.13 reported that electrical field stimula-
tion (EFS) of isolated strips of rabbit corpus cavernosum 
resulted in the endogenous generation and release of NO, 
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Figure 2.  Penile erection is regulated by two opposing 
systems: pro-erectile mediators such as nitric oxide (NO) and 
vasoactive intestinal peptide (VIP) and anti-erectile mediators 
such as noradrenaline (NA), endothelin-I, angiotensin II and 
thromboxane A2.
Figure 1. The nerve supply of the penis. From Eardley  
and Sethia.8
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nitrite and cGMP. These were the first published results to 
suggest that penile erection is mediated by NO generated in 
response to NANC stimulation.
Immuno-histochemical studies have demonstrated that 
the enzyme neuronal nitric oxide synthase (nNOS) is pre-
sent in the nerve fibres of the pelvic plexus, corpus caver-
nosum and around blood vessels.14
NO may be released from both the endothelium via 
eNOS and the nitrergic nerves via nNOS. Nitrergic-derived 
NO may be functionally more important, as nitrergic relax-
ation of the corpus cavernosum has been reported to not 
require a functional endothelium after removal by either 
physical15 or chemical means.15,16
Once released, NO exerts its action on smooth muscle cells 
by activating the enzyme sGC. The activation of sGC results 
in an increase in intracellular cGMP concentrations (Figure 
4).17 This in turn activates a number of second messenger sys-
tems which ultimately result in smooth muscle relaxation.
Pathophysiology of erectile 
dysfunction
ED can be caused by either psychogenic or organic fac-
tors; however, in many patients the disorder is of mixed 
aetiology with both factors contributing. The psycho-
genic component of ED is reported to be especially 
important in younger men (aged less than 35 years)18 and 
in elderly men who start a relationship with a new part-
ner. Diseases which become more prevalent with age 
such as diabetes and vascular disease are major risk fac-
tors in the ageing male. It has been reported that in 
patients older than 50, up to 50% may have ED secondary 
to vascular disease. The presence of ED of any aetiology 
is itself associated with psychological distress. This of 
course may in turn reduce the probability of achieving 
satisfactory erectile function.
Endothelial dysfunction
As ED and coronary artery disease share common risk fac-
tors, the concept of endothelial dysfunction has developed. 
Here ED is considered another manifestation of vascular dis-
ease specific to small vessels. ED can be considered to be an 
early manifestation of systemic endothelial dysfunction.19
It is now well established that ED often precedes and 
predisposes subsequent atherosclerosis. Moreover, 
endothelial dysfunction is a reflection of the loss of NO 
activity or biosynthesis at the endothelial level. This is 
associated with vasoconstriction, coagulation, leucocyte 
adhesion and smooth muscle cell hyperplasia, which is 
central to the process of atherosclerosis. The inhibition 
of eNOS (via impaired hydrolysis of dimethyl arginine) 
and the uncoupling of eNOS activity increase the oxida-
tive stress in the endothelial cells. This in turn results in 
further oxidative catabolism of NO and formation of 
peroxynitrite.
In diabetes-associated endothelial dysfunction, elevated 
free fatty acids which are seen in patients with insulin resist-
ance may induce endothelial dysfunction through the activa-
tion of protein kinase C (PKC), the increased production of 
reactive oxygen species (ROS), elevation in triglyceride and 
low-density lipoprotein (LDL), and decrease in high-density 
lipoprotein (HDL) levels.20 More recent evidence suggests 
that the effects of hyperglycaemia and insulin resistance on 
endothelial cells are additive, since defects in both glucose 
and lipid metabolism produce similar effects with the result-
ant decrease in endothelial NO availability.21 The associa-
tion between metabolic syndrome, insulin resistance and 
obesity and ED in men are now well characterised and 
understood.22
Figure 3.  Cross-section through shaft of penis demonstrating 
the sinusoids, subtunical venules and tunica albuginea. From 
Eardley and Sethia.8
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Figure 4.  Nitric oxide (NO) released from nitrergic nerves and 
endothelium stimulates smooth muscle relaxation by activation 
of soluble guanylate cyclase (sGC), which in turn catalyses 
the conversion of guanine triphosphate (GTP) to the active 
intracellular second messenger cyclic guanosine monophosphate 
(cGMP). cGMP is then metabolised by phosphodiesterase type 5 
(PDE5) to inactive GMP.
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Diabetes mellitus
Many epidemiologic studies have reported an increased 
risk of ED in diabetic men.23 The prevalence of ED has 
been reported to affect between 35% to 50% of diabetic 
patients.24 Furthermore, a positive relationship was demon-
strated between ED, poor metabolic control and age.25 
These results indicate that diabetes is a significant risk fac-
tor for the development of ED.
In diabetes, the severity of ED has been demonstrated to 
be related to both the severity26 and duration of diabetes.27 
However, it is likely that the aetiology of ED in diabetes is 
multifactorial. It is now well established that there is a 
higher incidence of peripheral neuropathy, autonomic neu-
ropathy, microangiopathy and arterial insufficiency in dia-
betic patients with ED than in potent diabetic patients.
The proposed mechanisms of ED in diabetics include: 
elevated advanced glycation end-products (AGEs) and 
increased levels of oxygen free radicals,28 impaired (NO 
synthesis, decreased and impaired cGMP-dependent 
kinase-1 (PKG-1),29 increased endothelin B (ETB) receptor 
binding sites and ultrastructural changes,30 upregulated 
RhoA/Rho-kinase pathway,31 endothelial dysfunction32 and 
NO-dependent selective nitrergic nerve degeneration.33
Therapeutic options for ED
Lifestyle modifications
The identification of specific risk factors associated with 
ED provides an opportunity for conservative measures in 
patients with mild to moderate ED. Cessation of smoking, 
weight loss and exercise are associated with an improve-
ment in erectile function, as well as improving endothelial 
function and reducing long-term cardiovascular risk.22
Pharmacological treatments for ED
There are a number of options available for the management 
of ED. They include oral agents, intracavernosal injection 
(papaverine, phentolamine, prostaglandin E1, vasoactive 
intestinal polypeptide (VIP)), transurethral vasoactive agents 
(prostaglandin E1), vacuum erection devices, penile revascu-
larisation surgery and insertion of a penile prosthesis.
Oral agents are the least invasive option and are the most 
accepted form of first-line treatment (Table 1).
PDE5 inhibitors
The second messenger cGMP is metabolised to GMP by a 
superfamily of enzymes called phophodiesterases (PDEs). 
Among all of the PDEs, PDE5, 6 and 9 are specific for 
cGMP, and PDE5 is the predominant PDE found in the cor-
pus cavernosum.34
Sildenafil (ViagraTM), vardenafil (LevitraTM) and tadala-
fil (CialisTM) are the currently available PDE5 inhibitors. 
Vardenafil is now also available as an orodispersible tablet 
(ODT).35 Newer PDE5 inhibitors avanafil (StendraTM) and 
udenafil have recently been approved by the Food and Drug 
Administration (FDA) in the United States (US). Tadalafil 
(once daily 5mg) has also recently been licensed for the 
treatment of both ED and symptoms related to benign pro-
static hyperplasia (BPH) by the FDA in the US.36 Udenafil, 
unlike the other PDE5 inhibitors, may also have a second 
mechanism of action. In animal models it has been found to 
increase ICP whilst reducing levels of the pro-contractile 
mediator endothelin 1, acting as an inhibitor of nNOS 
(asymmetric dimethylarginine (ADMA)).37
All of the PDE5 inhibitors have the same mechanism of 
action. However, they differ in their efficacy for the inhibi-
tion of the enzyme, in their selectivity for PDE5 over other 
isoenzymes such as PDE6 and in their pharmacological 
properties.
Potency and selectivity.  The potency of the PDE5 inhibitors 
can be measured in vitro by assessing the IC50 value (concen-
tration at which the enzyme activity is 50% inhibited). Using 
these values, vardenafil exhibits a PDE5 inhibitory poten-
tial approximately five times higher than that of sildenafil38 
(Table 2). PDE6 plays an important role in the conversion of 
light impulses into nerve impulses in the retina. For PDE6, 
sildenafil and vardenafil show a lower selectivity than tada-
lafil. With respect to PDE11, tadalafil shows only five times 
greater selectivity than does PDE5. PDE11 has been detected 
in a variety of human tissues, e.g. in the heart, pituitary gland, 
brain and testes. The physiological significance of PDE11 
and the possible consequences of its inhibition have not yet 
been fully established.
Pharmacokinetics. All four drugs are rapidly absorbed 
from the gastrointestinal tract, with peak plasma levels being 
attained within one hour in the case of sildenafil and varde-
nafil and after two hours in the case of tadalafil.39 For avana-
fil, it has been reported that peak levels are achieved within 
33 minutes.40 Food intake causes no delay or reduction 
in tadalafil absorption, whereas it is known to reduce and   
delay absorption of sildenafil. The mean half-lives (t1/2) of 
Table 1.  Oral agents for the treatment of male erectile 
dysfunction.
Oral treatments Mechanism of action
Sildenafil citrate (ViagraTM) PDE5 inhibitor
Tadalafil (CialisTM) PDE5 inhibitor
Vardenafil hydrochloride 
(LevitraTM)
PDE5 inhibitor
Avanafil (StendraTM) PDE5 inhibitor
Udenafil PDE5 inhibitor
Yohimbine α-adrenoceptor 
antagonist
Apomorphine (UprimaTM, 
IxenseTM and TaluvianTM)
Dopamine receptor 
agonist
PDE5: phosphodiesterase type 5.
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sildenafil and vardenafil are three to four hours; for avanafil 
it is five to 10 hours whereas that of tadalafil is approxi-
mately 18 hours.39 The elimination of sildenafil, vardenafil 
and tadalafil takes place predominantly via cytochrome 
enzyme P450 (CYP3A4) in the liver.39
Clinical efficacy. Results from clinical trials suggest that 
all three currently available PDE5 inhibitors are effective 
in a wide range of patient groups.41–43 Treatment with var-
denafil at a dose of 20 mg produced an improvement in the 
ability to achieve an erection in 80% of ED patients. In a 
comparable study of sildenafil (100 mg dose), 84% of ED 
patients were successfully treated. Treatment with tadalafil 
20 mg produced an improvement in the ability to achieve 
an erection in 81% of ED patients. Comparative studies 
between vardenafil and sildenafil44 and more recently tada-
lafil and sildenafil45 suggest that patients do not have a sig-
nificant preference among the PDE5 inhibitors.
Adverse effects. The most common side effects seen 
with sildenafil include headache, flushing, dyspepsia and 
rhinitis.46 The adverse effects with tadalafil and vardena-
fil are similar to sildenafil; however, tadalafil is associated 
with a higher incidence of back pain (4%–9%) and myalgia 
(1%–7%).
Difficult treatment groups
Diabetes mellitus
The sildenafil Diabetes Study Group reported that 56% of 
men with ED and diabetes who received sildenafil (25–100 
mg) for 12 weeks reported improved erections (Global 
Assessment Questionnaire (GAQ)). With placebo only 
10% reported better erections.47 In a more recent double-
blind, placebo-controlled, flexible-dose study patients were 
randomised to receive sildenafil or placebo for 12 weeks. 
The erectile function domain of the International Index of 
Erectile Function (IIEF) showed only a six-point increase 
in the mean score over placebo (Figure 5). However, men 
with mild/moderate ED achieved a higher overall score 
compared with men with severe ED.48
In a multicentre, double-blind, placebo-controlled, fixed-
dose trial, patients with diabetes and ED were randomized 
to take vardenafil or placebo as needed for 12 weeks. With 
respect to the erectile function domain, the dose-dependent 
final scores for the 10- and 20-mg dose were 17.1 and 19.0 
compared with 12.6 for placebo.49 Similar results have been 
reported in a prospective, randomised study in PDE5 inhib-
itor-naive patients with type 1 diabetes. Vardenafil treatment 
significantly improved the erectile function domain score of 
the IIEF (from 13 to 20)50 (Figure 5).
For tadalafil, at doses of 10 mg or 20 mg, the erectile 
function domain score was improved by 6.4 and 7.3, respec-
tively, regardless of baseline HbA1c levels51 (Figure 5).
Table 2.  Pharmacological properties of three PDE5 inhibitors: Sildenafil, vardenafil, tadalafil and avanafil are shown as “time to 
onset” and “duration of action” obtained from clinical studies.
Sildenafil Vardenafil Tadalafil Avanafil
Time to onset 30–60 min 25–40 min 45 min 15–30 min
Duration of action 4–8 hours Up to 6 hours 24–36 hours 4–6 hours
IC50 for PDE5 (nM) 3.5–3.7 0.1–0.7 0.9–1.8 N/A
aPDE1 80 500 >4450  
aPDE2 >8570 44,290 >14,800  
aPDE3 4630 >7140 >14,800  
aPDE4 2190 43,570 >14,800  
aPDE5 1 1 1  
aPDE6 10 16 190  
aPDE7 6100 >214,000 >14,800  
aPDE8 8500 >214,000 >14,800  
aPDE9 750 4150 >14,800  
aPDE10 2800 21,200 >14,800  
aPDE11 780 1160 5  
PDE5: phosphodiesterase type 5; IC50: concentration at which the enzyme activity is 50% inhibited. IC50 values are from in vitro enzyme studies.  
aDenotes the ratio of IC50 for that PDE enzyme over IC50 for PDE5.39
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Figure 5. The change in erectile function (EF) domain of the 
IIEF in non-diabetic patients compared with diabetic patients 
after treatment with sildenafil 100 mg,48,51 vardenafil 20 mg43,50 
and tadalafil 20 mg.52,53
IIEF: International Index of Erectile Function.
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For the newly launched PDE5 inhibitor avanafil, the 
results of the REVIVE ED study were recently presented. 
These results suggest that erections sufficient for penetra-
tion (SEP2) were found in 63% of patients versus 42% with 
placebo, and successful intercourse was possible (SEP3) in 
40% (versus 20% for placebo). Moreover, it was reported 
that over 70% of participants were able to achieve an erec-
tion within 15 minutes.
Testosterone replacement therapy
Androgens are known to be involved in both the central and 
peripheral pathways associated with penile erection. Tes-
tosterone is required for NOS expression in the corpus   
cavernosum and also for the maintenance of the neural 
pathway. Although controversial, testosterone supplemen-
tation is an option in patients with erectile dysfunction who 
are non-responders to PDE5 inhibitors and have a low 
serum testosterone level.54,55 Studies have suggested that up 
to 60% of non-responders may be converted to responders 
following combination treatment.56
Alternative oral treatment options
Apomorphine
The PVN in the hypothalamus is involved in initiating the 
erectile response. Apomorphine hydrochloride is a dopa-
minergic receptor agonist (D1 and D2 receptors) that has 
been developed as a sublingual agent to activate oxytocin-
ergic neurons in the PVN. The median onset to action is 19 
minutes and the half-life is one hour. An open-label, ran-
domised, flexible-dose comparison of apomorphine and 
sildenafil demonstrated the superior efficacy of sildenafil to 
apomorphine (75% versus 35%, respectively). The side 
effect profile – nausea (7%), dizziness (6.5%) and yawning 
(8.1%) – combined with a high non-responder rate has lim-
ited the therapeutic acceptance of this drug and has led to 
its withdrawal from the market.
α-adrenoceptor antagonists
The aim of these agents is to reduce the corpus cavernosum 
smooth muscle tone by inhibiting the innervation of the 
sympathetic nervous system. These agents are not routinely 
used in clinical practice as we now know that the NO-
cGMP signalling system is the predominant pathway in 
achieving smooth muscle relaxation.
Yohimbine is an orally administered indolalquino-
lonic alkaloid agent with both peripheral α2 adrenergic 
receptor blockade and central noradrenergic agonist 
activity. Phentolamine is a non-selective α-adrenoceptor 
antagonist, but has not gained acceptance – partly 
because of the associated systemic effects. The selective 
α1 antagonists doxazosin and terazosin are routinely 
utilised for patients with bladder outflow obstruction 
and can improve erectile function in patients with very 
mild symptoms.
Intracavernosal and intraurethral 
prostaglandins
The synthetic PGE1 analogue alprostadil can be adminis-
tered as a second-line therapy in patients failing oral phar-
macotherapies or who have a specific contraindication to 
treatment with oral agents. PGE1 increases the intracellular 
concentrations of the second messenger cAMP, resulting in 
corpus cavernosum smooth muscle relaxation. Currently, 
two methods of administration are available: direct intracav-
ernosal injection (80% response rate) or intraurethral appli-
cation of a small pellet (MUSE® dose 250–1000 μg, 65% 
response rate). This second-line treatment is useful in 
patients with long-standing diabetes or ED secondary to pel-
vic surgery, who have a higher incidence of ED refractory to 
oral pharmacotherapies.
A recent study suggests that a poor response to intracav-
ernosal alprostadil is associated with small vessel disease 
and a higher risk of cardiovascular events.57
Mechanical interventions
Vacuum devices
These devices are useful in patents with psychogenic or 
organic ED and can be used alone or in combination with 
other therapies. An external cylinder is utilised to create a 
negative pressure and penile tumescence is maintained by 
means of a constriction ring at the base of the penis. The 
reported patient satisfaction rate is 50%–70%.58
Penile prosthesis surgery
The insertion of a penile prosthesis is suitable for patients 
with severe organic ED. Two main subtypes of prosthesis 
are available: malleable (or semi-rigid) and inflatable. The 
malleable devices have the advantages of decreased 
mechanical breakdown, easier placement and lower cost. 
Inflatable devices are available as two- (Ambicor, Ameri-
can Medical Systems) or three-piece devices (AMS 700CX 
or Coloplast Titan, Titan Zero Degree). The two- and three-
piece devices have a pump placed in the scrotum that con-
trols the inflation and deflation of the device and therefore 
requires an element of patient dexterity.
Complications include infection rates of up to 2%–3% 
and re-operation rates for mechanical failure of 15% by 
10 years. The overall satisfaction rates have been reported 
as over 90% from the patients and partners, respec-
tively.59 Using a minimal handling approach and antibi-
otic-coated implants, infection rates have fallen to less 
than 1%60 (Figure 6).
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Future therapeutic options
Rho-kinase inhibitors
Rho-A is a small monomeric G protein that activates rho-
kinase and is involved in the sensitisation of the smooth 
muscle contractile elements to Ca2+. Therefore, smooth 
muscle relaxation can be modulated without a change in 
the intracellular Ca2+ levels. Rho-kinase inhibitors pro-
vide an alternative pathway to produce smooth muscle 
relaxation, and in vitro studies have shown that specific 
inhibitors of rho-kinase such as Y-27632 can cause a con-
centration-dependent relaxation of the corpus caverno-
sum.61
Direct sGC activators
Patients with significant endothelial dysfunction or nitrer-
gic nerve impairment are unable to produce adequate 
endogenous NO. Therefore, direct NO-independent activa-
tion of sGC provides a novel approach. The benzylindazole 
derivative YC-1 has been investigated as a potential sGC 
activator, but has been found to have non-specific phospho-
diesterase inhibitory activity – although alternative com-
pounds based on this prototype have been developed and 
are under investigation.62
NO-releasing PDE5 inhibitors
Sildenafil nitrate is an NO-releasing derivative of sildenafil 
citrate that can release NO spontaneously and can also 
inhibit PDE5. This compound is more potent than sildenafil 
citrate and can release NO in the absence of endogenous 
NO. Further research is required before any clinical appli-
cation is proposed.63
Further strategies for the 
treatment of ED
ED is invariably the result of a number of pathophysiologi-
cal events which result in a reduction in the bioavailability 
of NO. We believe that future strategies for the treatment of 
ED should be aimed at correcting or treating the underlying 
mechanisms involved in the pathogenesis of ED as well as 
finding more specific and effective sGC activators and NO-
releasing compounds.
Novel research areas include gene therapy with neuro-
trophic factors, eNOS, nNOS and superoxide dismutase. 
Through the use of an appropriate vector, diabetic animals 
have already been successfully transfected with these 
agents. Direct injections into the cavernous sheath of dia-
betic rats with neurotrophin-3 (NT3) using the herpes sim-
plex virus as the vector have been performed. Subsequent 
immunoreactive strains have demonstrated a significant 
increase in nNOS neurons in the major pelvic ganglia. 
Moreover, this was associated with significant increases in 
the ICP following cavernous nerve stimulation.64
Moreover, diabetic rats injected with adenoviruses con-
taining eNOS into the corpus cavernosum have produced 
significant rises in ICP secondary to cavernous nerve stim-
ulation. This was further associated with a rise in eNOS 
(measured by Western blot analysis) and an increase in 
NOS biosynthesis (measured by an increase in cavernous 
nitrate and nitrite formation).65
Further studies have examined the intracavernous injec-
tion of adenoviruses containing superoxide dismutase into 
diabetic rats. The results indicate a decrease in superoxide 
anion levels, an increase in NO bioavailability and an 
increase in cGMP levels.28
More recently, the effects of gene transfer on erectile 
function and sexual behaviour have evaluated in male cyn-
omolgus monkeys with ED and an ageing rat model. The 
animals were injected intracavernously with a smooth-
muscle-specific gene transfer vector (pSMAA-hSlo) 
encoding the pore-forming subunit of the human large- 
conductance, calcium-sensitive potassium channels 
(Maxi-K). The results have a shown a significant improve-
ment in erectile function and sexual behaviour66 or 
increased ICP responses to cavernous nerve stimulation67 
after the intracorporeal gene transfer. These results support 
the concept that intracorporeal Maxi-K-channel gene trans-
fer may be a novel way of improving erectile function.
Conclusion
Despite major advances in the understanding of the physi-
ology of penile erection and the pathophysiology of ED, 
together with an increase in the available pharmacothera-
pies, ED remains a significant global male health problem. 
This condition has an impact on the patients’ and partners’ 
quality of life and self-esteem.
Figure 6. The AMS 700CX three-piece inflatable implant. 
The implant is made up of two cylinders that are placed inside 
the corpus cavernosum, a momentary squeeze pump which is 
placed in the scrotum and a reservoir which is located in the 
retropubic space.
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Oral tablets, in particular PDE5 inhibitors, have revolu-
tionised the treatment of ED by decreasing reliance on 
more invasive options. Three potent selective PDE5 inhibi-
tors, sildenafil (Viagra; Pfizer), tadalafil (Cialis; Lilly) and 
vardenafil (Levitra; Bayer) are currently available in the 
United Kingdom. Although large multicentre clinical trials 
have shown the efficacy and tolerability of these drugs in 
ED with various aetiologies and a broad range of severity, 
30%–35% of patients fail to respond to oral pharmacother-
apies, especially in difficult treatment groups such as dia-
betic patients. The possible reasons for failure include 
severe ED at presentation, worsening of endothelial dys-
function, ED after radical prostatectomy or diabetes, unrec-
ognised or untreated hypogonadism, inadequate patient 
education or incorrect drug usage or the development of 
drug tolerance. However, end-stage surgical treatment 
using penile prosthesis surgery is still associated with a 
high patient and partner satisfaction rate of over 80%. The 
continued refinement of penile prostheses has resulted in 
reduced infection and mechanical failure rates.
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